<DOC>
	<DOCNO>NCT00639808</DOCNO>
	<brief_summary>The purpose study determine whether TZP-101 safe people diabetes . Also determine TZP-101 effective increase gastric empty rate diabetic patient .</brief_summary>
	<brief_title>Safety Efficacy IV Infusion Investigational Agent ( TZP-101 ) Patients With Diabetic Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Subject type 1 type 2 diabetes mellitus Subject document diagnosis gastroparesis : Delayed gastric empty ( gastric retention ≥60 % 2h ≥10 % 4 h ; base scintigraphy 4h standardized radionuclide solid meal ) A minimum 3 month history chronic upper abdominal discomfort ( two : chronic postprandial fullness , bloating , epigastric discomfort , early satiety , belch meal , postprandial nausea , vomit ) Subject normal upper endoscopy If female , must permanently sterilize postmenopausa . Patient receive investigational drug within precede 30 day Patient take unstable dos medication affect gastric motility Patient comorbid condition Patient positive laboratory test result hepatitis B , hepatitis C , HIV , control substance . Patient history psychiatric disorder ( include drug alcohol addiction ) require care psychiatrist psychologist within precede 12 month . Patient recent , adult history clinically significanthypersensitivity reaction ( ) drug . Patient known history alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>delay gastric empty</keyword>
	<keyword>symptomatic gastroparesis</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>